The company posted adjusted earnings of 50 cents per share, missing the 54 cents per share anticipated by analysts, according to FactSet data. This bottom-line miss overshadowed a narrow revenue beat, as the company reported $493.8 million in quarterly sales—a slight year-over-year decline that still surpassed the $486.2 million consensus.

Financial Performance and Outlook

While adjusted figures disappointed, Pediatrix saw its quarterly net income rise to $33.7 million, or 40 cents per share, up from $30.5 million in the prior-year period. The stock’s sharp retreat to $19.18 marks a significant correction for a ticker that has otherwise gained 36% over the last 12 months.

Looking ahead, the company issued preliminary guidance for 2026, projecting adjusted EBITDA between $280 million and $300 million. This range largely aligns with the $284.7 million forecast currently held by Wall Street analysts.